DREAMM-10

Phase 3 Clinical Trial Comparing the Safety and Efficacy of Belantamab Mafodotin, Lenalidomide and Dexamethasone Versus Daratumumab, Lenalidomide and Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma who are Ineligible for Autologous Stem Cell Transplant

What's the purpose of the trial?

The goal of this clinical trial is to compare the safety and efficacy of belantamab mafodotin combinated with lenalidomide and dexamethasone to the combination of daratumumab, lenalidomide and dexamethasone in participants who have newly diagnosed multiple myeloma and are not eligible for autologous stem cell transplantation.

Trial status

Accepting patients

Phase
Phase 3
Enrollment
520
Last Updated

Participating Centers

There are 29 centers participating in this trial. Enter a location below to find the closest center.

Experimental Treatments

Learn more about the experimental treatments being evaluated in this clinical trial.

  • Daratumumab
  • Dexamethasone
  • Lenalidomide
  • Belantamab Mafodotin

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print Report

Print this trial to share with your doctor.

(888) 828-2206

We can help answer any questions and connect you (or your patient) with the study team.

Schedule Call

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.